The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Levin O.S.

Rossiĭskaia meditsinskaia akademiia poslediplomnogo obrazovaniia

Babkina O.V.

Russian Medical Academy of Postgraduate Education, Moscow, Russia

A role of the MAO-B inhibitor rasagiline in treatment of Parkinson’s disease

Authors:

Levin O.S., Babkina O.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(7): 94‑100

DOI: 10.17116/jnevro20161167194-100

Read: 3678 times

Download PDF (RU)
Contact the author
Table of contents

A ROLE OF THE MAO-B INHIBITOR RASAGILINE IN TREATMENT OF PARKINSON’S DISEASE
A ROLE OF THE MAO-B INHIBITOR RASAGILINE IN TREATMENT OF PARKINSON’S DISEASE

To cite this article:

Levin OS, Babkina OV. A role of the MAO-B inhibitor rasagiline in treatment of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(7):94‑100. (In Russ.)
https://doi.org/10.17116/jnevro20161167194-100

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Neurochemical mechanisms of tremor in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):64-72
Clinical presentation and diagnosis of Parkinson’s disease in patients with schi­zophrenia spectrum diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):73-80
Cognitive impairment in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):81-90
Bladder dysfunction in patients with stages I—III of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):91-99
Chro­nic epidural spinal cord stimulation for gait impairments in Parkinson’s disease and atypical parkinsonism. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):100-112
A portrait of a doctor with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):160-164
Clinical and epidemiological indi­cators of stroke during the COVID-19 pandemic and in the post-COVID period in the Moscow region. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12-2):5-11
Comparative analysis of the resu­lts of treatment of gastric polyps by methods of loop electroexcision, laser and endo­scopic poly­pectomy with aspi­ration capture. Endo­scopic Surgery. 2024;(6):24-30
Black Acanthosis: Diagnosis and Treatment Issues. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(6):709-712
Resu­lts of the All-Russian consensus conference on complications in bariatric surgery. Endo­scopic Surgery. 2025;(1):15-24
Abstract:

The current medications for Parkinson’s disease (PD) treatment have predominantly symptomatic action. They reduce the severity of main motor symptoms and delay the disability and fatal outcome but do not able to prevent the late stages characterized by multiple motor and non-motor disorders. A search for new drugs, which are able to slow disease progression at the early stage and promote effective treatment of symptoms at the late stage, is extremely urgent. Rasagiline (azilect), a new generation MAO-B inhibitor, helps to solve the problems at different stages of PD.

Keywords:

Parkinson’s disease
treatment
MAO-B inhibitor
rasagiline

Authors:

Levin O.S.

Rossiĭskaia meditsinskaia akademiia poslediplomnogo obrazovaniia

Babkina O.V.

Russian Medical Academy of Postgraduate Education, Moscow, Russia

Close metadata

References:

  1. Golubev VL, Levin JaI, Vejn AM. Bolezn' Parkinsona i sindrom parkinsonizma. M.: MEDpress; 1999. (In Russ.).
  2. Shtok VN, Ivanova-Smolenskaja IA, Levin OS. Jekstrapiramidnye rasstrojstva. M.: MEDpress-inform; 2002. (In Russ.).
  3. Youdim MBH, Riederer PF. Monoamine oxidase A and B inhibitors in Parkinson’s disease. Koller W.C., Melamed E. (eds) Parkinson’s disease and related disorders. Edinburg: Elsevier; 2007;84:93-120. doi: 10.1016/S0072-9752(07)84034-6
  4. Shtok VN, Fedorova NV. Lechenie parkinsonizma. M. 1997. (In Russ.).
  5. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP patients requiring levodopa. Ann Neurol. 199;39:37-45. doi: 10.1002/ana.410390107
  6. Stocchi F. Rasagiline: defining the role of a novel therapy in the treatment of Parkinson’s disease. Int J Clin Pract. 2006;60:2:215-221. doi: 10.1111/j.1742-1241.2006.00806.x
  7. Horstink M, Tolosa E, Bonuccelli UG, Deuschl G, Friedman A, Kanovsky P, Larsen JP, Lees A, Oertel W, Poewe W, Rascol O, Sampaio C. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the EFNS and MDS-ES. Part II: late (complicated) Parkinson's disease. Eur J Neurol. 2006;13:1186-1202. doi: 10.1111/j.1468-1331.2006.01548.x
  8. Pahwa R, Factor SA, Lyons KE, Ondo WG, Gronseth G, Bronte-Stewart H, Hallett M, Miyasaki J, Stevens J, Weiner WJ. Practice Parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology. 2006;66:983-995. doi: 10.1212/01.wnl.0000215250.82576.87
  9. Chen JJ, Ly AV. Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease. Am J Health Syst Pharm. 2006;63:915-928. doi: 10.2146/ajhp050395
  10. Rabey JM, Sagi I, Huberman M, Melamed E, Korczyn A, Giladi N, Inzelberg R, Djaldetti R, Klein C, Berecz G. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol. 2000;23:324-330. doi: 10.1097/00002826-200011000-00005
  11. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol. 2004;61:561-566. doi: 10.1001/archneur.61.4.561
  12. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol. 2005;62:241-248. doi: 10.1001/archneur.62.2.241
  13. Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, Tolosa E. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO study). Lancet. 2005;365:947-954. doi: 10.1016/s0140-6736(05)71083-7
  14. Thebault JJ, Guillaume M, Levy R. Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor. Pharmacotherapy. 2004;24:1295-1305. doi: 10.1592/phco.24.14.1295.43156
  15. Smith K, Eyal E, Weintraub D, for the ADAGIO Investigators. Combined Rasagiline and Antidepressant Use in Parkinson Disease in the ADAGIO Study Effects on Nonmotor Symptoms and Tolerability. JAMA Neurol. 2015;72(1):88-95. doi: 10.1001/jamaneurol.2014.2472
  16. Levin OS. Razvitie motornyh fluktuacij u bol'nyh s razlichnymi stadijami bolezni Parkinsona. Atmosfera. Nervnye bolezni. 2005;1:10-16. (In Russ.).
  17. Blandini F. Neuroprotection by rasagiline: a new therapeutic approach to Parkinson's disease? CNS Drug Rev. 2005;11:183-194. doi: 10.1111/j.1527-3458.2005.tb00269.x
  18. Mandel S, Weinreb O, Amit T, Youdim MBH. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Brain Res Rev. 2005;48:379-387. doi: 10.1016/j.brainresrev.2004.12.027
  19. Bar-Am O, Amit T, Youdim MB. Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro. J Neurochem. 2007;103:500-508. doi: 10.1111/j.1471-4159.2007.04777.x
  20. Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E. A doubled-blind, delayed-start trial of rasagiline in Parkinson’s disease. The New England Journal of Medicine. 2009;361:1268-1278. doi: 10.1056/nejmoa0809335
  21. Hauser RA, McDermott MP, Messing S. for the Parkinson Study Group. Factors associated with development of motor fluctuations and dyskinesias in Parkinson’s disease. Arch Neurol. 2006;63:1756-1760. doi: 10.1001/archneur.63.12.1756
  22. Hely MA, Morris JG, Reid WG, Trafficante R. Sydney multicenter study of Parkinson’s disesase: Non-L-dopa-responsive problems dominate at 15 years. Mov Disord. 2005;20:90-199. doi: 10.1002/mds.20324
  23. Parkinson Study Group. Levodopa and progression of Parkinson disease. NEJM. 2004;351:2498-2508. doi: 10.1056/nejmoa033447
  24. Levin OS. Sovremennye podhody k diagnostike i terapii fluktuacij pri bolezni Parkinsona. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2006;12:74-80. (In Russ.).
  25. Panisset M. Freezing of gait in Parkinson’s disease. Neurol Clin. 2004;22:53-62. doi: 10.1016/j.ncl.2004.05.004
  26. Rabey JM, Fitzer-Attas C. Effect of adjunct rasagiline on dopaminergic and non-dopaminergic motor features of Parkinson disease. Eur J Neurol. 2007;14:1:1134.
  27. Mínguez-Mínguez S, Solís-García del Pozo JSG, Jordán J. Rasagiline in Parkinson’s disease: A review based on meta-analysis of clinical data. Pharmacological Research. 2013;74:78-86. doi: 10.1016/j.phrs.2013.05.005
  28. Elmer L, Schwid S, Eberly S, Goetz C, Fahn S, Kieburtz K, Oakes D, Blindauer K, Salzman P, Oren S, Prisco UL, Stern M, Shoulson I. Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms. J Neurol Sci. 2006;248:78-83. doi: 10.1016/j.jns.2006.05.014
  29. Goetz CG, Schwid SR, Eberly SW, Oakes D, Shoulson I. The Parkinson Study Group TEMPO and PRESTO Investigators. Safety of rasagiline in elderly patients with Parkinson disease. Neurology. 2006;66:1427-1429. doi: 10.1212/01.wnl.0000210692.95595.1c
  30. Demarcaida JA, Schwid SR, White WB, Blindauer K, Fahn S, Kieburtz K, Stern M, Shoulson I. Parkinson Study Group TEMPO, PRESTO Tyramine Substudy Investigators and Coordinators. Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline. Mov Disord. 2006;21:1716-1721. doi: 10.1002/mds.21048
  31. Panisset M, Schwid SR, Ondo W et al. Safety of concomitant therapy with rasagiline and antidepressants in Parkinson’s disease. Mov disord. 2007;22:16:340.
  32. Sader-Mazbar O, Loboda Y, Rabey MJ, Finberg JP. Increased L-DOPA-derived dopamine following selective MAO-A or -B inhibition in rat striatum depleted of dopaminergic and serotonergic innervation. Br J Pharmacol. 2013;170(5):999-1013. doi: 10.1111/bph.12349
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.